EXECUTIVE TEAM
img

Mark Blumling

CEO, Founder, and Board Member mark.blumling@headlandsresearch.com

A passionate advocate of healthcare and life sciences innovation, Mark has devoted his career to improving population health and patient outcomes. Mark was previously CEO of Genos, a healthcare big data company (which he co-founded and which was acquired in 2017), CEO of Relevare Pharmaceuticals (a drug development pharmaceutical company based in San Francisco and Australia), and Founder and COO of Hyperion Therapeutics (NASDAQ: HPTX; acquired in 2015). Mark began his career in the Office of Science & Technology at SmithKline Beecham, where he was involved in the creation and development of new business ventures, and at Orchid Biosciences (NASDAQ: ORCH), where he helped lead the company’s successful turnaround.

Mark received a JD from Stanford Law School, an MSc (Economics) from the London School of Economics, and a BA in Human Biology from Stanford University. He is a Member of the Council on Foreign Relations.

img

Lauren Chazal

Vice President of Global Strategic Alliances lauren.chazal@headlandsresearch.com

Lauren Chazal has a strong command of the clinical trials industry from a site operations, business development and financial management perspective. She began her career in clinical trial operations with a privately-held multi-site clinical research organization. Since 2012, she has held a pivotal role in business development and relationship management for clinical research sites globally. Lauren has in-depth knowledge of the complex interactions between clinical research centers, CROs and sponsors combined with a keen understanding of the importance of access to high quality trial sites and patient recruitment solutions.

Lauren graduated from Lehigh University with a dual degree in Finance and Marketing and from the University of Florida with a Master's in Business Administration (MBA). Lauren is a current member of Healthcare Businesswomen’s Association (HBA) and International Women’s Forum (IWF) Arizona Chapter as well as a four time marathon runner.

Meet Lauren Q&A

img

Cathy Collins

Senior Vice President Site Strategy/Development cathy.collins@headlandsresearch.com

Cathy Collins brings over 29 years of clinical trial experience to the Headlands team. Her background includes extensive de novo site development (Clinical Studies, LTD and Meridien) as well as site PE backed acquisition/integration (Protocare trials). She is the former owner/CEO of Meridien Research a 5 site, dedicated site organization and Insearch, a business development provider which were both sold to private equity (2012). Prior to joining the Headlands team, Cathy has served as the President and CEO of Clinical Consulting Solutions (CCS), a full-service clinical trials consulting firm providing consulting services spanning new site start-up, therapeutic development, financial/process improvement, and pre-acquisition PE due diligence (2014).

Cathy hold Bachelors and Master’s degrees in nursing and is a 2015 graduate of the Harvard Business School OPM program. She serves on a number of boards in her community including the Bank of Tampa and University of Tampa.

img

Heather Abbis

Vice President of Finance heather.abbis@headlandsresearch.com

Heather Abbis brings over 25 years of operational and corporate finance experience to Headlands. Her experience spans start-ups to large public companies in the US and Europe with life science and medical device companies. Her focus has always been on process improvement and internal controls that enable financial operations to run more smoothly and enhance governance. She has a record of successfully managing change through growth and acquisitions, implementing systems, building teams and business partnerships. Her experience covers the full accounting cycle and planning for growth that will be a key factor as the Headlands network grows.

Heather received her MBA in international business from European University and holds a Bachelor of Science degree in Accounting from Rochester Institute of Technology.

img

Adrian Milton

Vice President and General Counsel adrian.milton@headlandsresearch.com

Adrian Milton joined Headlands Research as Vice President and General Counsel, with over a decade of experience across multiple industries. Prior to joining Headlands, Adrian served as Deputy General Counsel of an S&P 500 company. In this role, he advised on a diverse array of matters, ranging from corporate transactional matters, mergers and acquisitions, joint ventures, corporate governance to debt and equity financing. In addition to legal advisory responsibilities, his innovative and forward-thinking strategies contributed to the company’s asset base and profile growth. He led and participated in shareholder engagement efforts, large- and small-scale M&A transactions and integrations amongst other initiatives. He began his career at Latham & Watkins LLP, where he served clients across industries in unique and complex corporate and securities matters.

Adrian earned a JD from the University of Chicago Law School and a BBA in International Business and Marketing from the University of Oklahoma.

Meet Adrian Q&A

img

James N. Goldenberg, MD - CPI, FAAN, FAPCR

Chief Medical Officer and Key Opinion Leader - Neurology james.goldenberg@headlandsresearch.com

Dr. James Goldenberg is a Board-Certified Neurologist who practiced in Palm Beach County, Florida for 25 years. He currently serves as Chief Medical Officer for Headlands Research and Sr. Vice President and Associate Medical Director of JEM Research Institute.

He previously served as Medical Director for Atlantic Coast Health Network, a regional super clinically integrated network (CIN), representing over 1,900 physicians and 200,000 lives in South Florida. In that role he is responsible for strategy, value-based care initiatives, population health and patient safety.

Dr. Goldenberg has served JFK Hospital in Atlantis Florida in multiple leadership roles including Chairman of the Board of Trustees Dr. Goldenberg has also served The Joint Commission as a disease-specific surveyor in stroke, the first physician to hold that position nationally. Dr. Goldenberg is an Affiliated Assistant Professor of Neurology at the Leonard M. Miller School of Medicine at the University of Miami.

Dr. Goldenberg is an advocate for patients and physicians at the local, regional, and national levels. He is a past president of the Palm Beach County Medical Society and currently serves on the Board of Directors. He has served the Florida Medical Association on the Board of Governors and the Council on Medical Economics and Practice Innovation. He is serving the American Academy of Neurology on the Board of Directors, Advocacy Committee, and chairs the Business Innovation Subcommittee.

His undergraduate training is in Psychology from the University of Florida. He received his Medical Degree from the University of South Florida. His neurology training and fellowship in neuromuscular disease were completed at the University of Miami.

Meet James Q&A

img

Sarah Buck

Senior Director of Human Resources sarah.buck@headlandsresearch.com

As the Senior Director of Human Resources, Sarah brings 20 years of generalist and specialist HR tenure to Headlands. Her experience includes Recruitment, Labor/Employee Relations, M&As, Org Design, and Business Partner leadership roles where she worked with executives to implement results-driven people strategies. She possesses expertise in creating and implementing best in class HR programs, while navigating through accelerated growth and high-change environments. Sarah’s career spans multiple industries, most recently in healthcare where she led HR for a growing 33 site medical network which doubled its size in less than three years. Her passion for blending company objectives with the recognition of employees as individuals will propel Headlands as a best place to work.

Sarah received her Master’s degree in Industrial Relations from the University of Wisconsin-Madison and holds a Bachelor of Human Resource Management from the University of Northern Iowa.

Meet Sarah Q&A

img

Chris Cugliari

Director of Corporate Development chris.cugliari@headlandsresearch.com

Chris Cugliari joined Headlands Research as Director of Corporate Development and brings a demonstrated history of capturing full value of M&A transactions. He was previously the Manager of Corporate Development and Strategy for Sotera Health, where his leadership drove significant growth and expanded the company’s total addressable market in the lab testing and contract sterilization segments for medical devices and pharmaceuticals. As a previous M&A consultant for PwC, Chris served clients across a wide range of industries and sizes through complex deal issues. His deep transactional knowledge from targeted prospecting through robust due diligence and integration helps position Headlands Research for growth.

Chris graduated from Columbia Business School with an MBA and from the University of Notre Dame with a BBA in Information Technology Management.

Meet Chris Q&A

img

Christian Sebastian

Director of Marketing christian.sebastian@headlandsresearch.com

Christian Sebastian joined Headlands Research as Director of Marketing. Christian brings 20+ years of marketing experience across industries including health care, financial services, manufacturing and insurance. From startups to tenured assignments in large multi-national organizations, Christian has seasoned expertise spanning marketing, digital strategy, MarTech, operations, automation and business intelligence. As a multi award-winning marketer, he is passionate about crafting and implementing innovative marketing solutions built upon an agile framework.

Christian received a Double Masters (Master of E-Commerce and Master of Business Administration) from Dalhousie University, a Bachelor of Commerce from McGill University and a KMP Certification.

Meet Christian Q&A

BUSINESS DEVELOPMENT
img

Lauren Chazal

Vice President of Global Strategic Alliances lauren.chazal@headlandsresearch.com

Lauren Chazal has a strong command of the clinical trials industry from a site operations, business development and financial management perspective. She began her career in clinical trial operations with a privately-held multi-site clinical research organization. Since 2012, she has held a pivotal role in business development and relationship management for clinical research sites globally. Lauren has in-depth knowledge of the complex interactions between clinical research centers, CROs and sponsors combined with a keen understanding of the importance of access to high quality trial sites and patient recruitment solutions.

Lauren graduated from Lehigh University with a dual degree in Finance and Marketing and from the University of Florida with a Master's in Business Administration (MBA). Lauren is a current member of Healthcare Businesswomen’s Association (HBA) and International Women’s Forum (IWF) Arizona Chapter as well as a four time marathon runner.

Meet Lauren Q&A

img

Mauro Ormedilla

Director of Business Development mauro.ormedilla@headlandsresearch.com

Hailing from Buenos Aires, Argentina, Mauro brings over 8 years’ experience leading clinical research sites. He has been responsible for business development, operations, accounting, finance, marketing, advertising, recruitment, QA, start-up, and regulatory teams. Prior to joining Headlands, Mauro served as the Director of Operations for a multi-site clinical research group, which grew ten-fold during his tenure. His passion lies in making connections – trials to patients, Sponsors/CROs to sites, CROs to Sponsors, and new friends to old.

Mauro graduated from the University of California San Diego with a degree in Human Development and received his MBA from Loyola University in New Orleans. He loves to golf, play basketball, and watch the Mardi Gras floats parade down St. Charles Avenue.

Meet Mauro Q&A

img

McKenzie Lang

Associate Director of Business Development mckenzie.lang@headlandsresearch.com

McKenzie Lang possesses a deep understanding of clinical research through her years of experience representing sites within the US and internationally. McKenzie understands the importance of clinical trials and how site networks play an integral role in expediting the drug development process. McKenzie has worked for several site organizations, including Bioclinica and Wake Research, over the past decade and understands the importance of strong collaborative Industry relationships that benefit patients. McKenzie is located in Raleigh, NC.

McKenzie graduated from East Carolina University with a B.S. in Biology.

Meet McKenzie Q&A

img

Kayla Kramschuster

Global Feasibility Analyst kayla.kramschuster@headlandsresearch.com

Kayla Kramschuster joined the Headlands Research team as the Global Feasibility Analyst. Kayla has previous work experience in the healthcare realm and Clinical Trials research in particular. Most recently as a Clinical Trials Data Coordinator for the Precision Medicine Team at the University of Wisconsin's Carbone Cancer Center. Kayla will be working closely with the Business Development team to deliver robust feasibilities to Headlands sites within defined scope and timelines.

Kayla graduated from the University of Wisconsin with a B.S degree in Community and Environmental Sociology and Environmental Studies and currently lives in Madison, Wisconsin with her dog Brady.

Meet Kayla Q&A

OPERATIONS
img

Cathy Collins

Senior Vice President Site Strategy/Development cathy.collins@headlandsresearch.com

Cathy Collins brings over 29 years of clinical trial experience to the Headlands team. Her background includes extensive de novo site development (Clinical Studies, LTD and Meridien) as well as site PE backed acquisition/integration (Protocare trials). She is the former owner/CEO of Meridien Research a 5 site, dedicated site organization and Insearch, a business development provider which were both sold to private equity (2012). Prior to joining the Headlands team, Cathy has served as the President and CEO of Clinical Consulting Solutions (CCS), a full-service clinical trials consulting firm providing consulting services spanning new site start-up, therapeutic development, financial/process improvement, and pre-acquisition PE due diligence (2014).

Cathy hold Bachelors and Master’s degrees in nursing and is a 2015 graduate of the Harvard Business School OPM program. She serves on a number of boards in her community including the Bank of Tampa and University of Tampa.

img

James N. Goldenberg, MD - CPI, FAAN, FAPCR

Chief Medical Officer and Key Opinion Leader - Neurology james.goldenberg@headlandsresearch.com

Dr. James Goldenberg is a Board-Certified Neurologist who practiced in Palm Beach County, Florida for 25 years. He currently serves as Chief Medical Officer for Headlands Research and Sr. Vice President and Associate Medical Director of JEM Research Institute.

He previously served as Medical Director for Atlantic Coast Health Network, a regional super clinically integrated network (CIN), representing over 1,900 physicians and 200,000 lives in South Florida. In that role he is responsible for strategy, value-based care initiatives, population health and patient safety.

Dr. Goldenberg has served JFK Hospital in Atlantis Florida in multiple leadership roles including Chairman of the Board of Trustees Dr. Goldenberg has also served The Joint Commission as a disease-specific surveyor in stroke, the first physician to hold that position nationally. Dr. Goldenberg is an Affiliated Assistant Professor of Neurology at the Leonard M. Miller School of Medicine at the University of Miami.

Dr. Goldenberg is an advocate for patients and physicians at the local, regional, and national levels. He is a past president of the Palm Beach County Medical Society and currently serves on the Board of Directors. He has served the Florida Medical Association on the Board of Governors and the Council on Medical Economics and Practice Innovation. He is serving the American Academy of Neurology on the Board of Directors, Advocacy Committee, and chairs the Business Innovation Subcommittee.

His undergraduate training is in Psychology from the University of Florida. He received his Medical Degree from the University of South Florida. His neurology training and fellowship in neuromuscular disease were completed at the University of Miami.

Meet James Q&A

img

Alana Wriggins

Vice President of Operations alana.wriggins@headlandsresearch.com

Alana Wriggins has more than 20 years of clinical research experience. She started her research career as a study coordinator at the Medical University of South Carolina and has since held leadership roles at Allergan, Forest Laboratories and Novartis. Her significant experience spans clinical trial execution as well as operations. At every stage, Alana has maintained a strong focus on quality. Alana has been involved at the front-line of numerous site and sponsor inspections both in the US and globally.

Alana is passionate about sponsor and site relationships. She has spearheaded several initiatives to partner with site networks and engage naïve investigators. Alana received her Bachelor of Science degree in Nursing from the University of South Carolina and her Master’s degree in Clinical Research Administration from George Washington University.

Meet Alana Q&A

img

Hank Heller

Director of Operations hank.heller@headlandsresearch.com

Hank Heller joined Headlands Research to lead budget and contract negotiations and project manage the implementation of new technological solutions. Hank previously was the Corporate Director of Strategic Operations for a multi-center PE owned research network. Hank started his clinical research career as a Regulatory Specialist for Compass Research and has held multiple positions in site operations, including Operations Coordinator for the Compass Phase I unit, Business Analyst for Bioclinica Research, and Site Director for Meridien Research. Hank's diverse clinical trial experience includes Phase I-IV trials and spans multiple therapeutic indications.

Hank graduated from the University of Florida with a B.A. in Economics.

img

Taylor Rice

Director of Site Development taylor.rice@headlandsresearch.com

Taylor Rice joined the Headlands Research team as the Director of Site Development. Taylor has over 7 years of clinical research experience with a comprehensive view of clinical site development. She possesses a strong aptitude for strategic clinical operations with a diligent focus on incorporating quality assurance. Prior to joining the Headlands team, she directed the Neurodegenerative Unit at Bioclinica. While at Bioclinica Taylor led the Neurodegenerative Unit to be recognized as one of the top Neurology Research Units in the world and consistently achieved top enroller status across multiple indications such as Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Lewy Body Dementia, and healthy Alzheimer’s prevention trials. Before Bioclinica she held multiple roles at Compass Research. Taylor will be focused on further developing current sites and will lead Headland’s upcoming de-novo CNS projects.

Taylor has a BS degree in Molecular and Microbiology from the University of Central Florida and lives in Orlando, Florida with her dogs Marly Mae and Ruby.

BOARD MEMBERS
img

Mark Blumling

CEO, Founder, and Board Member mark.blumling@headlandsresearch.com

A passionate advocate of healthcare and life sciences innovation, Mark has devoted his career to improving population health and patient outcomes. Mark was previously CEO of Genos, a healthcare big data company (which he co-founded and which was acquired in 2017), CEO of Relevare Pharmaceuticals (a drug development pharmaceutical company based in San Francisco and Australia), and Founder and COO of Hyperion Therapeutics (NASDAQ: HPTX; acquired in 2015). Mark began his career in the Office of Science & Technology at SmithKline Beecham, where he was involved in the creation and development of new business ventures, and at Orchid Biosciences (NASDAQ: ORCH), where he helped lead the company’s successful turnaround.

Mark received a JD from Stanford Law School, an MSc (Economics) from the London School of Economics, and a BA in Human Biology from Stanford University. He is a Member of the Council on Foreign Relations.

img

Cathy Collins

Senior Vice President Site Strategy/Development cathy.collins@headlandsresearch.com

Cathy Collins brings over 29 years of clinical trial experience to the Headlands team. Her background includes extensive de novo site development (Clinical Studies, LTD and Meridien) as well as site PE backed acquisition/integration (Protocare trials). She is the former owner/CEO of Meridien Research a 5 site, dedicated site organization and Insearch, a business development provider which were both sold to private equity (2012). Prior to joining the Headlands team, Cathy has served as the President and CEO of Clinical Consulting Solutions (CCS), a full-service clinical trials consulting firm providing consulting services spanning new site start-up, therapeutic development, financial/process improvement, and pre-acquisition PE due diligence (2014).

Cathy hold Bachelors and Master’s degrees in nursing and is a 2015 graduate of the Harvard Business School OPM program. She serves on a number of boards in her community including the Bank of Tampa and University of Tampa.

img

Anuv Ratan

Headlands Board Member

Anuv Ratan joined KKR in 2017 and is a member of the Health Care industry team. At KKR, he has been involved with investments in Gamma Biosciences, Impel Neuropharma, Headlands Research, BrightSpring Pharmerica, Global Medical Response, Ajax Health, and Aimmune Therapeutics. He is currently a member of the board of directors of Gamma Biosciences, Blue Sprig Pediatrics, and Headlands Research. Prior to joining KKR, Mr. Ratan was with FFL Partners, where he was involved in a number of health care transactions. Mr. Ratan began his career at The Blackstone Group. He holds an A.B., with honors, in Neurobiology from Harvard University.

img

Ali Satvat

Headlands Board Member

Ali J. Satvat joined KKR in 2012 and is a Member of KKR on the Health Care industry team within KKR’s Americas Private Equity platform. He leads KKR’s Health Care Strategic Growth investing efforts, sits on the Health Care Strategic Growth Investment Committee and is Chairman of the Health Care Strategic Growth Portfolio Management Committee. He currently serves on the boards of directors of AcuFocus, Arbor Pharmaceuticals, Blue Sprig Pediatrics, BridgeBio Pharma, Clarify Health Solutions, Cohera Medical, Coherus BioSciences, Eidos Therapeutics, Headlands Research, Impel NeuroPharma, Slayback Pharma, and Trilogy MedWaste and has been involved in KKR’s investments in Ajax Health, PRA Health Sciences, and Spirox. Previously, he held various positions with Apax Partners, Johnson & Johnson Development Corporation, Audax Group, and The Blackstone Group. Mr. Satvat holds an A.B., magna cum laude, in History and Science from Harvard College and an M.B.A. in Health Care Management and Entrepreneurial Management from the Wharton School of the University of Pennsylvania. He is a member of the board of directors of the Healthcare Private Equity Association.

ADVISORS
img

Roger Bullock M.D.

CMO, Oryzon Genomics

Dr. Roger Bullock completed his pre-clinical medical training at Keble College, Oxford University, gaining a BA (Hons) in Physiological Sciences in 1978 (converted to MA in 1985). This was followed by clinical medical training at St Bartholomew's Hospital in London where he gained the MB.BS in 1981.

In 1990, he specialized in psychiatry, gained membership of The Royal College of Psychiatry and undertook postgraduate psychiatric training including higher specialist training in geriatric psychiatry which concluded in 1993. Dr. Bullock is considered a world KOL in the space of neurodegenerative diseases. He has extensive experience as clinical researcher, having participated in more than 70 clinical trials in Alzheimer’s disease and other CNS conditions. Over his 30-year research career, he has authored and co-authored more than 100 peer-reviewed publications and book chapters in this domain and presented at numerous conferences. Recently he has been working as a consultant for companies active in the CNS space, including Lilly and Merck.

img

David Evans

CEO, Texas Neurology

David Evans is CEO of Texas Neurology, among the largest and most comprehensive neurology practices in the country. He is extremely active in the American Academy of Neurology where he currently serves as Chair of the AAN’s Practice Management & Technology Subcommittee and is Past Chair of the Business section. He is also a member of the AAN’s Medical Economics & Management Committee and BrainPAC Executive Committee. Mr. Evans has extensive background in practice management consulting with emphasis in the implementation of ancillary services within physician practices.

img

Craig Lipset

Former Head of Innovation, Pfizer

Craig Lipset is a recognized leader at the forefront of innovation in clinical research and medicine development. He is an advisor to technology and biopharmaceutical companies, leading universities, and the venture community, bringing vision and driving action at the intersection of research, digital solutions, and patient engagement. Craig was the Head of Clinical Innovation and Venture Partner at Pfizer, on the founding Operations Committee for TransCelerate Biopharma, and on the founding management teams for two successful startup ventures (Perceptive Informatics and Adnexus Therapeutics).

During that time, Craig designed and launched multiple industry firsts -- from the first fully remote/virtual clinical trial for a new medicine to the first returning of results and data to research participants. He currently serves on the Board of Directors for the Foundation for Sarcoidosis Research, the MedStar Health Research Institute, and the People-Centered Research Foundation (the central office for PCORnet), as well as on the Editorial Board for Therapeutic Innovation & Regulatory Science. Craig has received the red jacket 'hall of fame' recognition among the PharmaVOICE most inspiring people in the life sciences. He has been recognized among Pharmaceutical Executive’s Emerging Leaders, CenterWatch Top 20 Innovators in Clinical Trials, the Medicine Maker Power List and the AlleyWatch Who's Who in eHealth. He studied Music at Brandeis University and earned a Master of Public Health from Columbia.

img

Dr. Bola Oyegunwa PhD

Vice President and Head of Virtual Trials, Covance

Dr. Bola Oyegunwa is the Vice President and Head of Virtual trials at Covance. Bola is an industry thought leader in developing and implementing virtual trial solutions and disruptive technology offerings. Bola has led the implementation of innovative technology-enabled hybrid and virtual trials solutions for leading Biotech and pharmaceutical companies. Bola is a champion for reducing patient burden in clinical trials and regularly engages with regulatory authorities globally to remove regulatory barriers to the adoption of virtual clinical trials.

Bola is an ex-strategy consultant and has held leadership roles in Corporate Strategy, Product Development and Innovation at leading CROs. He holds a PhD in Microbiology and Immunology and a MBA from North Carolina State University.

img

Jane Restorick

Consultant and Managing Director, Arion Services

Jane Restorick is a recognized expert in site management, patient recruitment and clinical research operations. Prior to moving into consultancy, Jane was COO and Chief Patient Officer at Synexus Clinical Research, driving its growth from a UK based SMO to become a successful international operation across 11 countries. Previously she formed and led Operations and Quality Management teams at a virtual biopharma (Vanguard Medica) and at Fujisawa Early Clinical Evaluation Unit.

img

Steve Satek

CEO, Great Lakes Clinical Trials

Steve Satek is the Founder and President of Great Lakes Clinical Trials. Steve has more than 30 years of experience in the clinical research industry. He began his career as a bench researcher at the Northwestern University Robert H. Lurie Cancer Center and since that time has held senior management positions at the Chicago Center for Clinical Research, Radiant Research, Cognitive Drug Research and Forenap Pharma.

Steve offers a diverse and thorough knowledge of clinical trial operations, which has been presented at over 25 industry conferences. In addition, he has personally project managed and/or coordinated over 150 trials. Steve currently serves as the Planning Committee Chairman for the Global Site Solutions Summit, one the clinical research industry's leading conferences.

KEY OPINION LEADERS
img

Larry Bush - MD

Key Opinion Leader - Infectious Disease and Vaccine

Dr. Larry Bush has practiced the specialized field of Infectious Diseases in Palm Beach County, Florida, since 1989. He is involved in organized medicine and has served many roles, including President of the Palm Beach County Medical Society (PBCMS), which is a network of 1,500 physicians in the Palm Beach County area.

Dr. Bush has developed a portfolio of influential positions locally, regionally, and nationally. He is committed to the scientific process and has participated in a multitude of clinical trials throughout his career. He maintains close academic affiliations and is dedicated to educating the next generation of physicians, relishing the opportunity to teach students and residents.

Dr. Bush has held leadership positions in several hospitals including multiple positions as committee chair in Infectious Disease stewardship, credentialing, quality, pharmacy, research, and medical executive leadership. He has served on the Board of two local hospitals, culminating in a term as Board chair. He holds the academic positions of Affiliated Professor of Medicine at the Charles E. Schmidt College of Medicine at Florida Atlantic University as well as Affiliated Associate Professor of Medicine at University of Miami Miller School of Medicine. Through his academic affiliations, Dr. Bush has trained countless internal medicine residents, many of whom have gone on to fellowships and careers in Infectious Diseases.

Dr. Bush has authored over 90 peer-reviewed medical journal articles. He is a current associate editor of two national Infectious Diseases journals, and continues to author book chapters in medical reference literature and has conducted over 100 infectious disease research trials, including vaccine trials.

Dr. Larry Bush received his bachelor’s degree in Biology from the University of Pennsylvania and his Medical Degree from the Medical College of Pennsylvania. Subsequently, he did his residency in Internal Medicine at the Pennsylvania Hospital of the University of Pennsylvania Health System, where he went on to serve as Chief Medical Resident for one year. He completed specialty training as a fellow in Infectious Diseases at the Medical College of Pennsylvania before relocating to South Florida.

img

Sharon Cohen - MD, FRCPC

Key Opinion Leader - Neurology

Dr. Sharon Cohen is a behavioural neurologist known for her excellence in patient care, teaching, and clinical research. She completed her neurology residency and behavioural neurology fellowship at the University of Toronto. She is the medical director and site principal investigator of Toronto Memory Program, a community-based medical facility which she established in 1996 for the purpose of enhancing diagnosis, care, and therapeutic options for individuals with or at risk for Alzheimer’s disease and related disorders. Under her guidance, Toronto Memory Program’s multidisciplinary team has grown to a staff of 30 individuals. Its memory clinic and research site are among the most active in Canada.

Dr. Cohen has over 28 years of experience in clinical research and has been a site PI for over 100 pharmacological trials. She has participated in acute stroke trials as well as trials in FTD, PDD, DLB, HD, vascular dementia, and Alzheimer’s disease, the latter being her primary focus. Her site has been credited as a “go to” centre for Alzheimer’s trials and has been awarded for superior performance and quality in clinical research.

Dr. Cohen represents Canada on international advisory boards and steering committees and is a consultant to a wide range of stakeholders in dementia including government organizations and patient advocacy groups. She is a frequent lecturer and contributes to media events including those on medical ethics. She is known for her advocacy of individuals with neurodegenerative diseases.

Despite holding academic and hospital appointments, Dr. Cohen chooses to practice in the community, in keeping with her belief that dementia care and clinical research are best offered in the real world setting.

img

James N. Goldenberg - MD - CPI, FAAN, FAPCR

Chief Medical Officer and Key Opinion Leader - Neurology

Dr. James Goldenberg is a Board-Certified Neurologist who practiced in Palm Beach County, Florida for 25 years. He currently serves as Chief Medical Officer for Headlands Research and Sr. Vice President and Associate Medical Director of JEM Research Institute.

He previously served as Medical Director for Atlantic Coast Health Network, a regional super clinically integrated network (CIN), representing over 1,900 physicians and 200,000 lives in South Florida. In that role he is responsible for strategy, value-based care initiatives, population health and patient safety.

Dr. Goldenberg has served JFK Hospital in Atlantis Florida in multiple leadership roles including Chairman of the Board of Trustees Dr. Goldenberg has also served The Joint Commission as a disease-specific surveyor in stroke, the first physician to hold that position nationally. Dr. Goldenberg is an Affiliated Assistant Professor of Neurology at the Leonard M. Miller School of Medicine at the University of Miami.

Dr. Goldenberg is an advocate for patients and physicians at the local, regional, and national levels. He is a past president of the Palm Beach County Medical Society and currently serves on the Board of Directors. He has served the Florida Medical Association on the Board of Governors and the Council on Medical Economics and Practice Innovation. He is serving the American Academy of Neurology on the Board of Directors, Advocacy Committee, and chairs the Business Innovation Subcommittee.

His undergraduate training is in Psychology from the University of Florida. He received his Medical Degree from the University of South Florida. His neurology training and fellowship in neuromuscular disease were completed at the University of Miami.

Meet James Q&A

img

Vishaal Mehra - MD

Dr. Vishaal Mehra attended Texas A&M Health Science Center for his Medical Degree, and then completed his residency in Psychiatry at the University of California, San Diego. He began his career as an Investigator in clinical research in 2007.

As a Principal Investigator, Dr. Mehra worked in a variety of psychiatry and neurology therapeutic areas. He also worked closely with Sponsors and CROs to promote study-wide trial success, acting as a liaison for other Principal Investigators and the sponsor for several trials. Dr. Vishaal Mehra founded Artemis Institute for Clinical Research in 2008.

img

Mark A. Goldstein - MD CPI, FAPCR

Key Opinion Leader - Neurology

Dr. Goldstein was born and raised in New York City. He graduated Colgate University, receiving a B.A. degree with a major in Biophysics. He obtained his MD degree from Emory University School of Medicine in Atlanta. Upon graduation, he completed residencies in both Internal Medicine (College of Medicine and Dentistry of New Jersey/Robert Wood Johnson) and Neurology (Stanford University). He is board certified in both Internal Medicine and Neurology. After relocating to South Florida, he joined a busy clinical neurology practice which he helped grow to 6 Neurologists.

Dr. Goldstein began participating in clinical trials in the late 1990’s. To date, he has participated in over 80 clinical trials, being the Principal Investigator 70 times. Most of these trials have been conducted through JEM Research Institute, of which he is a founding member and the CEO. Under his guidance, JEM has grown into a substantial clinical research site currently employing 26 people, and conducting over 20 active trials at any one time, many of which deal with progressive cognitive decline.

As a clinical neurologist, Dr. Goldstein serves as an Affiliated Assistant Clinical Professor of Neurology at the University of Miami. As a researcher, he is a Certified Principal Investigator as well as a Fellow of the Academy of Physicians in Clinical Research.

Dr. Goldstein has served on the board of directors of the Medical Specialists of The Palm Beaches, the largest multispecialty medical group in Palm Beach County. He has also been a member of the executive committee as well as chairman of the credentials committee at JFK Hospital in Atlantis. He has been both the Chief of the Division of Neurology and the Director of the Comprehensive Stroke Center at JFK.

img

Nathan Segall - MD

Key Opinion Leader - Vaccine

Nathan Segall M.D. is a Certified Physician Investigator (CPI) and Principal Investigator and founder of Clinical Research Atlanta (CRA). He is well recognized in the pharmaceutical industry, successfully conducting over 400 (60+ vaccine) clinical trials since 1992 and authoring numerous articles and publications. Dr. Segall has practiced in the Atlanta area for more than 29 years. He is board certified in Internal Medicine as well as Pediatric and Adult Allergy & Immunology.